NVA237
NVA237 is a pharmaceutical drug with 21 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 18 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
2
Mid Stage
17
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
85.7%
18 of 21 finished
14.3%
3 ended early
0
trials recruiting
21
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment
A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.
Clinical Trials (21)
Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment
A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma
NVA237 BID Versus Placebo Twelve-week Efficacy Study
NVA237 Versus Placebo 12-week Efficacy Study
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients
Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium
Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 21